Fortress Biotech, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Fortress Biotech, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $74.00K, a 72.09% increase year-over-year.
- Fortress Biotech, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $44.00K, a 8.33% decline year-over-year.
- Fortress Biotech, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00.
- Fortress Biotech, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $43.00K, a 15.69% decline year-over-year.
- Fortress Biotech, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $87.00K, a 12.12% decline from fiscal 2024.
- Fortress Biotech, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $99.00K.
- Fortress Biotech, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2021 was $278.00K, a 9.88% increase from fiscal 2020.
- Fortress Biotech, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2020 was $253.00K, a 105.69% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $74.00K 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $87.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | |
| 2025-06-30 | $43.00K 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $99.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | |
| 2024-06-30 | $51.00K 10-Q · filed 2025-08-14 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | |
| 2022-06-30 | $99.00K 10-Q · filed 2023-08-14 | |
| 2021-12-31 | $141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $278.00K 10-K · filed 2022-03-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | |
| 2021-06-30 | $137.00K 10-Q · filed 2022-08-11 | |
| 2020-12-31 | $163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $253.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | $180.00K 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $90.00K 10-Q · filed 2021-08-16 | |
| 2019-12-31 | $63.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-09 | $123.00K 10-K/A · filed 2021-04-09 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | |
| 2019-06-30 | $60.00K 10-Q · filed 2020-08-10 | |
| 2018-12-31 | $70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $198.00K 10-K · filed 2020-03-16 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | |
| 2018-06-30 | $128.00K 10-Q · filed 2019-08-09 | |
| 2017-12-31 | $149.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $191.00K 10-K · filed 2019-03-18 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | |
| 2016-12-31 | $108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $189.00K 10-K · filed 2018-03-16 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | |
| 2015-12-31 | $59.00K 10-K · filed 2018-03-16 | |
| 2014-12-31 | $19.00K 10-K · filed 2017-03-16 | |
| 2013-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $92.00K 10-K · filed 2016-03-15 |
| 2012-12-31 | $87.00K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |